RHOXF2B and chronic myelogenous leukemia, BCR-ABL1 positive: We note that the mRNA expression of RHOXF2B (4/19 responses in primary vs 7/11 in boost), HBG (no responders at 12 weeks post-primary vaccination series, 2 responders at later time points) and CDC25C (1 responder post-primary, 3 responders post boost) all were overexpressed (5–40-fold) in K562 compared with primary CML-CP cells (Figure 5).